Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory…